|Application ||WB, IHC-P, IF, E|
|Other Accession||NP_001011550, 4103|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||Predicted: 35 kDa; Observed: 45 kDa|
|Application Notes||MAGEA4 antibody can be used for detection of MAGEA4 by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.|
|Target/Specificity||MAGEA4 antibody was raised against a 16 amino acid peptide near the amino terminus of human MAGEA4.|
The immunogen is located within the first 50 amino acids of MAGEA4.
|Reconstitution & Storage||MAGEA4 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year.|
|Precautions||MAGEA4 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Not known, though may play a role in embryonal development and tumor transformation or aspects of tumor progression.|
|Tissue Location||Expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma, but not in normal tissues except for testes and placenta|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
MAGEA4 is a member of the melanoma-associated antigen family that consists of a number of antigens recognized by cytotoxic T lymphocytes (1). MAGEA4 may serve as a target for antitumoral vaccination and may play a role in embryonal development and tumor transformation or aspects of tumor progression. It is expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma and have been implicated in some hereditary disorders, such as dyskeratosis congenital (2-4).
Bhan S, Negi SS, Shao C, et al. BORIS binding to the promoters of cancer testis antigens, MAGEA2, MAGEA3, and MAGEA4, is associated with their transcriptional activation in lung cancer. Clin. Cancer Res. 2011; 17:4267-76.
Bhan S, Chuang A, Negi SS, et al. MAGEA4 induces growth in normal oral keratinocytes by inhibiting growth arrest and apoptosis. Oncol. Rep. 2012; 28:1498-502.
Saito T, Wada H, Yamasaki M, et al. High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine. Vaccine, epub. 2014; S0264-410X(14)01217-1.
Zhang QM, He SJ, Shen N, et al. Overexpression of MAGE-D4 in colorectal cancer is a potentially prognostic biomarker and immunotherapy target. Int. J. Clin. Exp. Pathol. 2014; 7:3918-27.
If you have any additional inquiries please email technical services at email@example.com.